Navigation Links
Insulin from Saliva – Salimetrics Launches New Testing Protocol to Supplement Modern Obesity Research
Date:2/23/2017

Today, researchers can fast-track sample collection and analysis for multi-analyte studies (such as insulin, cortisol, CRP, adiponectin, uric acid, and/or other biomarkers or SNPs of interest) using one, easy-to-collect saliva sample. With the addition of the Salivary Insulin Assay from Salimetrics’ SalivaLab, the relationship between insulin and other relevant biomarkers can be extensively studied through a non-invasive sample type.

Salivary insulin maintains a near-linear correlation to fasting serum levels and is a reliable surrogate to serum measures, with a 0.92 correlation (Fabre 2012). Previous research also shows a ~30 minute delay of salivary insulin over the spike in serum insulin levels during an oral glucose tolerance test (Fekete 1993). Therefore, salivary insulin presents a unique opportunity for the research community to survey overweight or obese pre-symptomatic individuals as a convenient means to monitor insulin levels prior to disease progression. Elevated fasting insulin is a hallmark of insulin resistance, which can supersede TIID disease onset by several years and may be used to justify changes in lifestyle to reduce disease risk (Hayashi 2013).

With the validation and availability of salivary insulin, Salimetrics now provides access to a key metabolic marker to enable a new era in obesity research. When compared to alternative biological specimen types, Salivary Bioscience researchers report higher levels of efficiency and increased participant recruitment and retention. Additionally, salivary bioscience adds unique benefits to studies with large populations, frequent sampling and monitoring regimens, child-centric participant groups, and/or studies collecting multiple biomarkers and/or genetic data from the same sample without requiring highly trained individuals, a phlebotomist or on-site emergency personnel to monitor participants for adverse reactions.

Obesity is a major risk factor for a wide variety of conditions including cardiovascular diseases, hypertension, certain cancers, and type 2 diabetes. A key factor in minimizing the impact of the obesity epidemic is hinged on reducing the prevalence of childhood obesity and monitoring overweight and at-risk individuals early on in the disease progression. For instance, more frequent testing of fasting salivary insulin may identify children that are developing insulin resistance and progressing toward type 2 diabetes. “Researchers are currently exploring salivary insulin as a specific type 2 diabetes pre-screening method, so that preventative treatment can start before permanent damage or obesity related comorbidities occur,” says Steve Granger, Ph.D., Salimetrics CSO. “However, more research is required to fully understand insulin’s pathophysiology and integrate salivary diagnostics at a clinical level.” Recent research has also explored the utility of salivary insulin as a biomarker for metabolic disease risk (Goodson 2016) and a large number of reviews and meta-analyses show that increased concentrations of insulin correlate with BMI status (Hartman 2016).

Researchers in a multitude of interdisciplinary research fields are rapidly adopting salivary bioscience for studies where participant compliance is paramount to collecting biologically relevant datasets. Today, Salimetrics offers research tools and support for more than 25 analytes and DNA-related analysis in saliva samples. Since 1999, Salimetrics has been leading the integration of salivary bioscience into research studies and diagnostic applications by focusing on better results through high-quality tools, methodologies, and protocols that maintain the integrity of saliva as a biological specimen. Researchers are encouraged to contact the experts at Salimetrics to explore options for integrating salivary bioscience into research and ensure they maintain the most scientifically credible data.

To learn more about salivary insulin or how to incorporate saliva into your research, simply visit the Salimetrics website, or ask an expert.

References:
Goodson, JM, et al. (2014). Metabolic Disease Risk in Children by Salivary Biomarker Analysis. PLoS One. 9(6): e98799.

Fekete Z, et al. (1993). Salivary and plasma insulin levels in man. Biochem Mol Biol Int. 30(4): 623–629.

Fabre B, et al. (2012). Measurement of fasting salivary insulin and its relationship with serum insulin in children. Endocr Connect. 1(2): 58–61.

Hartman ML, et al. (2016). Unhealthy Phenotype as Indicated by Salivary Biomarkers: Glucose, Insulin, VEGF-A, and IL-12p70 in Obese Kuwaiti Adolescents. J Obes. 2016: 6860240.

Ebbeling CB, et al. (2002). Childhood obesity: public-health crisis, common sense cure. Lancet. 360(9331):473-82.

Zhao X, et al. (2016). Using Metabolomic Profiles as Biomarkers for Insulin Resistance in Childhood Obesity: A Systematic Review. J Diabetes Res. 2016:8160545.

D'Adamo E, et al. (2011). Type 2 diabetes in youth: epidemiology and pathophysiology. Diabetes Care. 34 Suppl 2:S161-5.

Hayashi T, et al. (2013). Patterns of Insulin Concentration During the OGTT Predict the Risk of Type 2 Diabetes in Japanese Americans. Diabetes. 36(5): 1229-1235.

About Salimetrics:
Salimetrics’ assay kits and CLIA-certified testing services are used to measure salivary analytes related to stress, behavior and development, inflammation, sleep, reproduction, health and immune function. Founded in 1998 by Douglas A. Granger, Ph.D., Salimetrics, LLC supports CROs, pharmaceuticals, academic researchers and the immunodiagnostic industry around the world with innovative immunoassay products, non-invasive saliva collection methods, and laboratory testing services.

Read the full story at http://www.prweb.com/releases/salivary-insulin/salimetrics/prweb14070898.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. No rebirth for insulin secreting pancreatic beta cells
2. Andain Inc. Announces 2,000 Units Initial Production of the Breakthrough Miniature Disposable Insulin Pump for Use in Clinical Trials for Type-I and Type-II Diabetes
3. Generex Collaborates with University Health Network for Buccal Insulin Project
4. Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets
5. Diasome Pharmaceuticals, Inc. Announces Issuance of Oral Insulin Patent by the US PTO
6. Clinical Studies & Research Substantiate Claims That Companys Targeted Healthy Nutritional Products Promote Healthy Lipids, Glucose & Insulin Levels
7. Generex Provides Update on Buccal Insulin Formulation Enhancement Project
8. Diasome Pharmaceuticals, Inc. Announces Notice of Allowance from US PTO for Liver Targeting System for Insulin
9. Oramed Submits Protocol to U.S. FDA for Its Phase IIb Oral Insulin Study
10. Basal Insulin Peglispro Studies Demonstrate Superiority to Insulin Glargine Across Multiple Measures in People with Type 1 Diabetes
11. Insulin Independence Revolutionary Phase 3 Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2018)... ... July 31, 2018 , ... Mahoney Environmental , ... of their new website. The new website has been designed with improved functionality ... with Proceed Innovative to build a website created for the customer. The newly ...
(Date:7/25/2018)... ... 25, 2018 , ... Dimitrius Anagnos, an evidence-based healer, today ... and autoimmune disorders. , The preclinical research assessed biomarkers for systemic and ... Over 70% decrease in Interleukin (IL-1ß) expression , ...
(Date:7/25/2018)... ... July 25, 2018 , ... ... Systems Innovator, joined the board of the Indiana India Business Council (IIBC), an ... elected today by the current board of directors, McDonald joins an impressive roster ...
(Date:7/24/2018)... ... July 24, 2018 , ... On August 6, ... SmartTRAK platform. Not just a pretty face, SmartTRAK 3.0’s latest improvements were ... SmartTRAK is the world’s first online and real-time data portal that specializes in ...
Breaking Biology Technology:
(Date:8/1/2018)... (PRWEB) , ... August 01, 2018 , ... ... portfolio, announces the release of Limfinity® version 7.1. Limfinity® is the software framework ... Limfinity® itself creates new possibilities for both current users and the future of ...
(Date:7/31/2018)... SAN DIEGO (PRWEB) , ... July 31, 2018 , ... ... cell analysis. The company has just introduced the xCELLigence RTCA S16, which ... Controlled and monitored via an external computer, the S16can be placed in any standard ...
(Date:7/30/2018)... ... July 30, 2018 , ... TC ... beneficial impact of biofield energy healing treated Vitamin D3 on the strength and ...     Over 260% increase in ALP, a bone-specific enzyme ,     Over ...
Breaking Biology News(10 mins):